This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Jeff Jonas Appointed President Of Shire Regenerative Medicine Business And Joins Shire Leadership Team

LA JOLLA, California, November 15, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Jeff Jonas M.D. has been appointed President of Shire's Regenerative Medicine (RM) business, effective November 15, 2012.  Jeff will report to Shire Chief Executive, Angus Russell, and will join the Shire Leadership Team.  

After a varied career in research & development, commercial and entrepreneurial business roles, Jeff joined Shire in July 2008 as leader of the Specialty Pharmaceuticals (SP) Research & Development (R&D) team.  

Jeff has been closely involved with the RM business since Shire acquired it as Advanced BioHealing in June 2011.  In addition to his role as head of the SP R&D team, Jeff has been leading the RM R&D team and has been a member of the RM leadership team.  Jeff will lead the newly established RM team to take the business to its next stage of growth.

Jeff's role as head of the SP R&D team will be filled by Arnaud Partiot M.D.  Arnaud is a qualified psychiatrist and has been a senior member of the Shire SP team in various clinical research & development, medical affairs and commercial roles since joining Shire in 2004.

Kevin Rakin, who led Advanced BioHealing Inc. since 2007 and during its integration into Shire, is stepping down from his position as Regenerative Medicine President and from the Shire Leadership Team to pursue new career interests.  Kevin will be available to provide transitional support through 28 December 2012.  

Says Shire Chief Executive, Angus Russell:

"We are pleased with the progress we are making in transforming our Regenerative Medicine business.  Jeff's insight and experience will enable us to build on this as we shape this business for future growth.  We have great ambition for this business and we're committed to seeing those ambitions realised."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs